A. Ghofrani (Giessen, Germany), G. Simonneau (Le Kremlin-Bicêtre, France)
LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study
G. Keir, T. Corte, L. Parfitt, T. Maher, P. Marino, E. Renzoni, K. Dimopoulos, M. Gatzoulis, B. Madden, L. Howard, P. Corris, K. O'Reilly, B. Hope-Gill, S. Birring, A. Wells, S. J. Wort (London, Newcastle upon Tyne, Southampton, Cardiff, United Kingdom; Sydney, Australia)
|   |
Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis
A. Seferian, L. Tu, A. Huertas, C. Phan, M. Le Hiress, N. Ricard, F. Perros, P. Dofmüller, G. Simonneau, M. Humbert, D. Montani, C. Guignabert (Le Kremlin Bicêtre, Le Plessis Robinson, France)
| |
Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study
E. Mayer, A. M. D'Armini, H. A. Ghofrani, E. Grünig, P. Jansa, N. H. Kim, G. Simonneau, A. Torbicki, C. Wang, M. R. Wilkins, N. Davie, A. Fritsch, M. M. Hoeper (Bad Nauheim, Giessen, Heidelberg, Wuppertal, Hannover, Germany; Pavia, Italy; Prague, Czech Republic; San Diego, United States Of America; Le Kremlin-Bicêtre, France; Warsaw, Poland; Beijing, China; London, United Kingdom)
|  |
Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study
V. Cottin, D. Montani, M. Reynaud-Gaubert, L. Kiakouama, H. Nunes, C. Dromer, B. Wallaert, C. Gomez, S. Quetant, D. Launay, E. Gomez, L. Bertoletti, J. Traclet, S. Polazzi, S. Zeghmar, A. M. Schott, M. Humbert, J. F. Cordier (Lyon, Paris, Marseille, Bobigny, Bordeaux, Lille, Grenoble, Nancy, Saint-Etienne, France)
| |
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study
E. Grünig, N. Galiè, M. Humbert, A. M. Keogh, D. Langleben, L. J. Rubin, R. Speich, A. Fritsch, N. Davie, H. A. Ghofrani (Heidelberg, Wuppertal, Giessen, Germany; Bologna, Italy; Le Kremlin-Bicêtre, France; Sydney, Australia; Montreal, Canada; La Jolla, United States Of America; Zurich, Switzerland)
| |
Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study
N. Galiè, F. Grimminger, E. Grünig, M. Humbert, Z. C. Jing, A. M. Keogh, D. Langleben, L. J. Rubin, M. Ochan Kilama, A. Fritsch, N. Davie, H. A. Ghofrani (Bologna, Milan, Italy; Giessen, Heidelberg, Wuppertal, Germany; Le Kremlin-Bicêtre, France; Shanghai, China; Sydney, Australia; Montreal, Canada; La Jolla, United States Of America)
| |
An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2)
G. Simonneau, A. M. D'Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. R. Wilkins, A. Fritsch, N. Davie, G. Weimann, E. Mayer (Le Kremlin-Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; Prague, Czech Republic; San Diego, United States Of America; Beijing, China; London, United Kingdom)
| |
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN)
H. A. Ghofrani, R. Channick, M. Delcroix, N. Galiè, P. Jansa, F. O. Le Brun, S. Mehta, C. Mittelholzer, T. Pulido, B. K. S. Sastry, O. Sitbon, R. Souza, A. Torbicki, L. Rubin, G. Simonneau (Giessen, Germany; Boston, San Diego, United States Of America; Leuven, Belgium; Bologna, Italy; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; Le Kremlin Bicêtre, France; São Paulo, Brazil; ECZ-Otwock, Poland)
| |